A Randomized Controlled Pilot Trial of Mesalazine in Patients With Irritable Bowel Syndrome

Irritable Bowel Syndrome Clinical Trial

Official title:

Effect of Mesalazine on Low Grade Mucosal Inflammation in Irritable Bowel Syndrome. A Pilot Double Blind Placebo Controlled Study.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00774007
• Other study ID #: IBS-01/03
• Status: Completed
• Phase: Phase 2/Phase 3
• First received: October 15, 2008
• Last updated: October 15, 2008
• Start date: September 2004
• Est. completion date: November 2005

Study information

• Verified date: October 2008
• Source: SOFAR S.p.A.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Italy: National Institute of Health
• Study type: Interventional

Clinical Trial Summary

Emerging evidence indicates the presence of low-grade mucosal inflammation and its pathogenetic role in IBS. The aim of this pilot study is to provide that mesalazine treatment of IBS patients reduces low grade colonic inflammation.

Description:

Emerging evidence indicates the presence of low-grade mucosal inflammation and its pathogenetic role in IBS. The aim of this pilot study is to provide that mesalazine treatment of IBS patients reduces low grade colonic inflammation.

This is a pilot double blind placebo controlled study.

A total of twenty patients (both males and females) will be recruited; ten will be randomly assigned to the placebo controlled arm and ten to the study medication arm.

Inclusion criteria:

• IBS patients (both males and females) with positive diagnosis based on Rome II criteria [20]

• age ≥ 18 years

• Patients capable of conforming to the study protocol;

• Patients who have given their free and informed consent

Exclusion criteria:

• Patients with ascertained Inflammatory Bowel Diseases (Crohn disease, Diverticular disease, Ulcerative colitis, Infectious colitis, Ischemic colitis, microscopic colitis); food intolerance/allergy; active malignancy of any type, or history of a malignancy; presence of major abdominal surgeries; ascertained hypersensitivity to the salicylates; positive faecal culture for bacterial, mycotic or parasitic pathogens; patients with history of clinically significant renal (creatinine ≥ 2.0 mg/dL or ≥177 μmol/L), hepatic (AST or ALT greater than three times the upper limit of normal range), cardiac, metabolic or haematological disease; esophageal, gastric or duodenal ulcer within 30 days prior to randomization; patients with intended or ascertained pregnancy; lactation; patients who become unable to conform to protocol; patients who are continuously taking laxatives; patients in antibiotic therapy during the last month; patients in current therapy with corticosteroids; treatment with any investigational drug within the previous 30 days; treatment with lactulose or with any compound that lowering the colonic pH can prevent the release of the active moiety; recent history or suspicion of alcohol abuse or drug addiction; any severe pathology that can interfere with the treatment or the clinical tests of the trial; previous participation in this study.

Treatments:

Mesalazine cpr 800 mg t.i.d. for 8 weeks Placebo cpr t.i.d. for 8 weeks

Primary End Points:

The primary end point of the study will be to assess the effect of mesalazine treatment on:

• Total number of inflammatory mucosal cells

Secondary End Points:

• Individual inflammatory cell subsets and enterochromaffin (EC) cells in the colonic mucosa (mast cells, macrophages, B and T lymphocytes subsets)

• Inflammatory release by mucosal biopsies

• Indicative measures of symptoms relief

The local tolerability of treatment, through the daily monitoring of intolerance manifestations at the gastrointestinal level, will be carried out by each patient and reported to the investigator on each control visit.

Adverse event(s) and concurrent illness(es) which occur during the study will be monitored.

The following laboratory test results will be recorded at Basal Visit (T0) and at the end of the study (T8):

• Hemochrome, AST , ALT, creatinine, γ-GT, alkaline phosphatase (AP), total bilirubin, glucose, N, Na+, K+, Ca 2+ Urine pregnancy test: if the patient is a female of childbearing potential, a urine pregnancy test will be performed and must be confirmed as negative before the first dose of study medication is administered.

On the BASAL VISIT (T0) the following will be performed:

1. Diagnosis of IBS disease based on Rome II criteria

2. Check inclusion and exclusion criteria

3. Written Consent

4. Record medical history and concomitant medication

5. Physical examination

6. Urine pregnancy test

7. Vital Signs (BP, HR, LR)

8. Fecal Culture

9. Sigmoid biopsy

10. Delivery of the patient's diary

11. Laboratory Assessments

12. Symptom questionnaire

On the VISITS T2, T4 and T6 ( after 2, 4 and 6 weeks) the following will be performed:

1. Symptom questionnaire

2. Vital Signs (BP, HR, LR)

3. Collection/Delivery of the patient's diary

4. Record Adverse Events

5. Record Concomitant Medication

On the VISIT T8 or FINAL VISIT (After eight weeks) the following will be performed:

1. Sigmoid biopsy

2. Symptom questionnaire

3. Collection/Delivery of the patient's diary

4. Physical examination

5. Laboratory Assessments

6. Vital Signs (BP, HR, LR)

7. Record Adverse Events

8. Record Concomitant Medication Data recorded during the study will be summarised by treatment group and compared using descriptive statistics.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: November 2005
• Est. primary completion date: November 2005
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• IBS patients (both males and females) with positive diagnosis based on Rome II criteria

• age = 18 years

• Patients capable of conforming to the study protocol;

• Patients who have given their free and informed consent

Exclusion Criteria:

• Patients with ascertained Inflammatory Bowel Diseases (Crohn disease, Diverticular disease, Ulcerative colitis, Infectious colitis, Ischemic colitis, microscopic colitis)

• Patients with ascertained food intolerance/allergy

• Patients with active malignancy of any type, or history of a malignancy (patients with a history of other malignancies that have been surgically removed and who have no evidence of recurrence for at least five years before study enrollment are also acceptable)

• Presence of major abdominal surgeries

• Ascertained hypersensitivity to the salicylates

• Positive faecal culture for bacterial, or parasitic pathogens

• Patients with history of clinically significant renal (creatinine = 2.0 mg/dL or =177 µmol/L), hepatic (AST or ALT greater than three times the upper limit of normal range), cardiac, metabolic or haematological disease

• Esophageal, gastric or duodenal ulcer within 30 days prior to randomization

• Patients with intended or ascertained pregnancy; lactation

• Patients who become unable to conform to protocol

• Patients who are continuously taking laxatives

• Patients in antibiotic therapy during the last month

• Patients in current therapy with corticosteroids

• Treatment with any investigational drug within the previous 30 days

• Treatment with lactulose or with any compound that lowering the colonic pH can prevent the release of the active moiety

• Recent history or suspicion of alcohol abuse or drug addiction

• Any severe pathology that can interfere with the treatment or the clinical tests of the trial

• Previous participation in this study

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Irritable Bowel Syndrome
• Syndrome

Intervention

Drug:
• mesalazine

• placebo

Locations

Country	Name	City	State
Italy	Department of Internal Medicine & Gastroenterology	Bologna

Sponsors (2)

Lead Sponsor	Collaborator
SOFAR S.p.A.	St. Orsola Hospital

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary endpoint in the study was to assess the effect of mesalazine treatment on total number of mucosal immune cells in the colonic mucosa of patients with IBS.		8 weeks	Yes
Secondary	Effect of mesalazine on: 1) mucosal immune cell subsets; 2) inflammatory mediator release from mucosal biopsies; 3) symptom relief, as detected by means of visual analogue scales.		8 weeks	Yes